BTIG Research Increases Compass Pathways (NASDAQ:CMPS) Price Target to $25.00

Compass Pathways (NASDAQ:CMPS) had its price target hoisted by investment analysts at BTIG Research from $14.00 to $25.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 93.66% from the stock’s previous close.

CMPS has been the subject of several other reports. Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Royal Bank Of Canada increased their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. B. Riley Financial began coverage on shares of Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 price objective for the company. Maxim Group lifted their price objective on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Finally, TD Cowen reiterated a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.20.

Compass Pathways Trading Up 0.5%

Shares of NASDAQ CMPS traded up $0.07 during midday trading on Tuesday, reaching $12.91. The company had a trading volume of 10,001,854 shares, compared to its average volume of 3,677,930. Compass Pathways has a one year low of $3.34 and a one year high of $15.40. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm’s fifty day moving average price is $11.63 and its 200-day moving average price is $8.43. The stock has a market cap of $1.74 billion, a PE ratio of -4.04 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, equities research analysts anticipate that Compass Pathways will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Corient Private Wealth LLC boosted its stake in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after acquiring an additional 1,200 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. Conservest Capital Advisors Inc. lifted its holdings in shares of Compass Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Compass Pathways during the fourth quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. boosted its position in shares of Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.